Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options.

Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol (2017) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78

Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87

Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2009) 4.90

2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2011) 4.48

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11

Good Health at Low Cost 25 years on: lessons for the future of health systems strengthening. Lancet (2013) 4.03

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med (2012) 3.96

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation (2008) 2.98

Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm (2009) 2.08

Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace (2013) 2.07

Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91

The global burden of stroke and need for a continuum of care. Neurology (2013) 1.87

The epidemiology of cardiovascular diseases in sub-Saharan Africa: the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog Cardiovasc Dis (2013) 1.77

Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 1.67

South African guideline for management of ischaemic stroke and transient ischaemic attack 2010: a guideline from the South African Stroke Society (SASS) and the SASS Writing Committee. S Afr Med J (2010) 1.66

Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2012) 1.62

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47

Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol (2014) 1.39

Warfarin reversal. J Clin Pathol (2004) 1.33

Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation (2014) 1.30

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26

Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol (2012) 1.26

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20

Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis (2009) 1.14

Strengthening Health Systems for Chronic Care: Leveraging HIV Programs to Support Diabetes Services in Ethiopia and Swaziland. J Trop Med (2012) 1.13

Global epidemiology of atrial fibrillation. Nat Rev Cardiol (2014) 1.12

Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study. Heart (2010) 1.10

Prevalence of stroke in an urban, mixed-income community in Lagos, Nigeria. Neuroepidemiology (2007) 1.08

Characteristics and outcomes of stroke at Tikur Anbessa Teaching Hospital, Ethiopia. Ethiop Med J (2005) 1.07

Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace (2010) 1.04

Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol (2013) 1.04

Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med (2006) 0.96

Heart failure in sub-Saharan Africa. Curr Cardiol Rev (2013) 0.94

'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM (2007) 0.93

Strikingly low prevalence of atrial fibrillation in elderly Tanzanians. J Am Geriatr Soc (2012) 0.86

Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi. Cardiovasc J Afr (2013) 0.86

Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost (2006) 0.86

[Atrial fibrillation: epidemiological data from the Cardiology Institute in Abidjan, Côte d'Ivoire]. Med Trop (Mars) (2010) 0.84

South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation. Cardiovasc J Afr (2011) 0.84

Prescribing patterns for the use of antithrombotics in the management of atrial fibrillation in Zimbabwe. Cent Afr J Med (1999) 0.83

Cost burden of post stroke condition in Nigeria: a pilot study. Glob J Health Sci (2012) 0.82

[Atrial fibrillation, frequency, etiologic factors, evolution and treatment in a cardiology department in Dakar, Senegal]. Pan Afr Med J (2010) 0.81

Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. S Afr Med J (2013) 0.81

Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area. Cardiovasc J Afr (2013) 0.81

Pathological sub-types, risk factors and outcome of stroke at the Nairobi Hospital, Kenya. East Afr Med J (2008) 0.81

Warfarin in non-valvular atrial fibrillation. S Afr Med J (2013) 0.78

Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation. Cardiovasc J Afr (2011) 0.77

Epidemiology of stroke in a rural community in Southeastern Nigeria. Vasc Health Risk Manag (2014) 0.76

Bayer's Xarelto® is approved in South Africa across five additional indications. Cardiovasc J Afr (2014) 0.76

A survey on the treatment of atrial fibrillation in South Africa. S Afr Med J (2014) 0.76

Electrocardiographic assessment of coronary artery disease and stroke risk factors in rural and urban Tanzania: a case-control study. J Stroke Cerebrovasc Dis (2013) 0.76